[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

JP2003503342A - ＭＴＰ阻害剤とＨＭＧ−ＣｏＡ還元酵素阻害剤との組み合わせ並びに薬剤におけるその使用 - Google Patents

ＭＴＰ阻害剤とＨＭＧ−ＣｏＡ還元酵素阻害剤との組み合わせ並びに薬剤におけるその使用

Info

Publication number
JP2003503342A
JP2003503342A JP2001505893A JP2001505893A JP2003503342A JP 2003503342 A JP2003503342 A JP 2003503342A JP 2001505893 A JP2001505893 A JP 2001505893A JP 2001505893 A JP2001505893 A JP 2001505893A JP 2003503342 A JP2003503342 A JP 2003503342A
Authority
JP
Japan
Prior art keywords
carbon atoms
branched
linear
chain
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001505893A
Other languages
English (en)
Japanese (ja)
Inventor
グリユツマン，ルーデイ
ミユラー，ウルリヒ
ビシヨフ，ヒルマー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of JP2003503342A publication Critical patent/JP2003503342A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2001505893A 1999-06-25 2000-06-13 ＭＴＰ阻害剤とＨＭＧ−ＣｏＡ還元酵素阻害剤との組み合わせ並びに薬剤におけるその使用 Pending JP2003503342A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19929065.2 1999-06-25
DE19929065A DE19929065A1 (de) 1999-06-25 1999-06-25 Kombination von MTP-Inhibitoren und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
PCT/EP2000/005410 WO2001000183A2 (de) 1999-06-25 2000-06-13 KOMBINATION VON MTP-INHIBITOREN UND HMG-CoA-REDUKTASE-INHIBITOREN UND IHRE VERWENDUNG IN ARZNEIMITTELN

Publications (1)

Publication Number Publication Date
JP2003503342A true JP2003503342A (ja) 2003-01-28

Family

ID=7912459

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001505893A Pending JP2003503342A (ja) 1999-06-25 2000-06-13 ＭＴＰ阻害剤とＨＭＧ−ＣｏＡ還元酵素阻害剤との組み合わせ並びに薬剤におけるその使用

Country Status (12)

Country Link
EP (1) EP1196194A2 (es)
JP (1) JP2003503342A (es)
AR (1) AR028996A1 (es)
AU (1) AU5680900A (es)
CA (1) CA2376881A1 (es)
DE (1) DE19929065A1 (es)
DO (1) DOP2000000022A (es)
GT (1) GT200000099A (es)
PE (1) PE20010302A1 (es)
SV (1) SV2004000109A (es)
UY (1) UY26218A1 (es)
WO (1) WO2001000183A2 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005021486A1 (ja) * 2003-08-29 2007-11-01 日本たばこ産業株式会社 エステル誘導体及びその医薬用途
JP2008538413A (ja) * 2005-04-22 2008-10-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング Ｍｔｐ阻害化合物をスクリーニングするための方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10030375A1 (de) * 2000-06-21 2002-01-03 Bayer Ag Verwendung von MTP-Inhibitoren zur Senkung von ppTRL
ZA200502496B (en) * 2002-02-28 2005-10-12 Japan Tobacco Inc Ester compound and medicinal use thereof.
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
US10905667B2 (en) 2018-07-24 2021-02-02 Bayer Pharma Aktiengesellschaft Orally administrable modified-release pharmaceutical dosage form
CN109053927A (zh) * 2018-08-08 2018-12-21 中山大学 一种含维生素b12基团的两亲性海藻酸钠衍生物及其制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08225526A (ja) * 1994-10-04 1996-09-03 Bayer Ag シクロアルカノ−インドールおよび−アザインドール誘導体
JPH09183766A (ja) * 1995-12-15 1997-07-15 Bayer Ag 二環式複素環式化合物
JPH09328466A (ja) * 1995-12-15 1997-12-22 Bayer Ag インドリル−置換されたフエニル酢酸誘導体
JPH1036372A (ja) * 1996-04-18 1998-02-10 Bayer Ag 新規なピリダジノ−、ピリミド−、ピラジノ−およびトリアジノ−インドール類
WO1998023593A1 (en) * 1996-11-27 1998-06-04 Pfizer Inc. Apo b-secretion/mtp inhibitory amides
WO1998050028A1 (en) * 1997-05-01 1998-11-12 Bristol-Myers Squibb Company Mtp inhibitors and fat soluble vitamin therapeutic combinations to lower serum lipid levels

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08225526A (ja) * 1994-10-04 1996-09-03 Bayer Ag シクロアルカノ−インドールおよび−アザインドール誘導体
JPH09183766A (ja) * 1995-12-15 1997-07-15 Bayer Ag 二環式複素環式化合物
JPH09328466A (ja) * 1995-12-15 1997-12-22 Bayer Ag インドリル−置換されたフエニル酢酸誘導体
JPH1036372A (ja) * 1996-04-18 1998-02-10 Bayer Ag 新規なピリダジノ−、ピリミド−、ピラジノ−およびトリアジノ−インドール類
WO1998023593A1 (en) * 1996-11-27 1998-06-04 Pfizer Inc. Apo b-secretion/mtp inhibitory amides
WO1998050028A1 (en) * 1997-05-01 1998-11-12 Bristol-Myers Squibb Company Mtp inhibitors and fat soluble vitamin therapeutic combinations to lower serum lipid levels

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005021486A1 (ja) * 2003-08-29 2007-11-01 日本たばこ産業株式会社 エステル誘導体及びその医薬用途
JP4832897B2 (ja) * 2003-08-29 2011-12-07 日本たばこ産業株式会社 エステル誘導体及びその医薬用途
JP2008538413A (ja) * 2005-04-22 2008-10-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング Ｍｔｐ阻害化合物をスクリーニングするための方法

Also Published As

Publication number Publication date
UY26218A1 (es) 2001-01-31
EP1196194A2 (de) 2002-04-17
DOP2000000022A (es) 2008-08-15
PE20010302A1 (es) 2001-04-12
DE19929065A1 (de) 2000-12-28
AR028996A1 (es) 2003-06-04
GT200000099A (es) 2001-12-13
WO2001000183A2 (de) 2001-01-04
AU5680900A (en) 2001-01-31
SV2004000109A (es) 2004-05-07
WO2001000183A3 (de) 2001-05-10
CA2376881A1 (en) 2001-01-04

Similar Documents

Publication Publication Date Title
KR20010093845A (ko) 피브레이트와 세리바스타틴의 복합제제
JP2003528928A (ja) β遮断薬およびコレステロール低下薬の新組合せ
JP2002508320A (ja) スタチン−カルボキシアルキルエーテル配合物
JP2003503342A (ja) ＭＴＰ阻害剤とＨＭＧ−ＣｏＡ還元酵素阻害剤との組み合わせ並びに薬剤におけるその使用
EA010373B1 (ru) Фармацевтические композиции, содержащие высшие первичные спирты и эзетимиб, и способ их получения
TWI290833B (en) Therapeutic agent for glomerular disease
KR100539066B1 (ko) 비정상적 지질대사-유래 질환치료에 유용한 스타틴과알카노일 ｌ-카르니틴 함유 약제 조성물
JP4901218B2 (ja) 併用医薬
US20040092571A1 (en) Pharmaceutical composition
US20080070938A1 (en) Medicinal composition for mitigating blood lipid or lowering blood homocysteine
CA2492781A1 (en) Medicinal composition for mitigating blood lipid or lowering blood homocystein
WO2004080488A2 (de) Kombinationspräparate von acetylsalicylsäure mit einem hmg-coa-reduktase
WO2001085155A1 (fr) Procede et compositions pour l'inhibition de l'arteriosclerose
JP2003535875A (ja) 新規製剤
EP1314423A1 (en) Medicinal compositions
WO2012092103A1 (en) Gemcabene and derivatives for treating pancreatitis
WO2005062718A2 (en) Methods of administering 3,3,14,14 tetramethyl hexadecane 1,16 dioic acid
WO2008015763A1 (fr) Formulation médicamenteuse contenant un médicament fibrate et procédé pour la produire
JP2003501385A (ja) Ｈｍｇ−ｃｏａレダクターゼ阻害剤とカルニチン類を含む抗高脂血症性組合せ
JP2002145774A (ja) 医薬組成物
CA2494801A1 (en) Medicinal composition containing hmg-coa reductase inhibitor
CA2384797A1 (en) Medicament combinations
JP2007008923A (ja) フィブラート系薬剤を含有する製剤及びその製造方法
KR20100109840A (ko) 분비성 포스포리파제 ａ2 (ｓｐｌａ2) 억제제를 사용한 심혈관 질환 및 이상지혈증의 치료 및 ｓｐｌａ2 억제제 조합 요법
KR20090035643A (ko) 피브레이트계 약제를 함유하는 제제 및 그의 제조 방법

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070523

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110726